Apollomics plans to lay off staff, narrow focus for lung cancer trial
Apollomics is making major cost cuts and leadership changes to stay afloat. The oncology biotech announced Wednesday morning that co-founder and president Sanjeev Redkar and chief medical officer Peony...
View ArticleClik here to view.
In biotech's uneven recovery, 50 startups raised megarounds in first half of...
The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens. If that pace continues, it could top the heydays of 2020 and 2021. In the...
View ArticleMississippi judge rejects efforts by Novartis, PhRMA to block 340B state law
A Mississippi federal judge has denied efforts by Novartis and industry trade group PhRMA to thwart a state law that would keep drugmakers from imposing some restrictions around the federal drug...
View ArticleExperts want to make it easier to get RSV vaccines. Did they make it harder...
Last week, experts on the CDC’s panel that sets vaccine recommendations created new guidance for who should get RSV shots heading into the second-ever season of vaccination for the respiratory disease....
View ArticleFederal judge rules against Boehringer Ingelheim in IRA lawsuit
A Connecticut federal judge threw out Boehringer Ingelheim’s case against the Inflation Reduction Act on Wednesday, marking another win for the federal government as the first Medicare negotiations...
View ArticleRoche’s TIGIT drug tiragolumab fails Phase 3 lung cancer trial
Roche will halt a late-stage study of tiragolumab after it failed to help certain lung cancer patients, adding to a string of registrational disappointments for the drug in recent years. The anti-TIGIT...
View ArticleAvid Bio’s 2024 revenue drops; Lotte Bio breaks ground on new $3.3B site
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Avid Bioservices’ revenue for fiscal year 2024 dropped by 6% to $140...
View ArticleUK’s PMCPA criticizes Novo, Novartis, Pfizer and Otsuka for code breaches
A British watchdog has criticized four drugmakers, including Novo Nordisk, for violating the Association of the British Pharmaceutical Industry’s code of practice, marking the third time the Danish...
View ArticleInnovent reworks deal with IASO; Granza raises $7M
Plus, news about Kvantify: China’s Innovent takes a stake in CAR-T partner: After bringing the BCMA CAR-T therapy Fucaso to market in China, Innovent and IASO Biotechnology are reworking their deal....
View ArticleCircle Pharma raises $54M as part of Series D while macrocycles heat up
Circle Pharma, a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D. The company recently closed the first part of the round, reeling in about $54...
View ArticleEli Lilly’s Alzheimer’s OK; GSK picks its mRNA bets; Megaround tally;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support
On the verge of raising its Series A in late 2021, Myricx Bio faced a tough choice. The toxicity profile for its IV and oral small molecules looked “like a key risk,” according to Myricx CEO Robin...
View ArticleVC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’
When Christopher Trummer tried raising money for his molecular glue degrader startup, he struggled to find VC support in his native Austria. The company, Celeris Therapeutics, had to leap to the US to...
View ArticleInventiva ramps up search for funding as cash runway erodes
As Inventiva continues to enroll patients into its Phase 3 liver disease program, it is seeking new funding to replenish its dwindling cash runway. The biotech had just €9.6 million ($10.4 million) in...
View ArticleClik here to view.
Lilly discloses its first biotech acquisition of the year, buying Morphic for...
Eli Lilly said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin drugs for chronic diseases, as the autoimmune space continues to drum up pharma...
View ArticleIdeaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397
Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain types of urothelial cancer and lung cancer. In...
View ArticleVanqua raises $45M; Aerovate to look for strategic alternatives
Plus, news about GSK, iTeos, Oxolife and SmallCella: Vanqua Bio reels in $45M: The Chicago neuroscience biotech extended its Series B, a spokesperson confirmed to Endpoints News. The company originally...
View ArticleClik here to view.
Gene insertion startup Komo Biosciences launches with new integrase...
Scientists at the University of Hawaii have improved tools for making large changes to genomes and have licensed the technology to a new startup called Komo Biosciences, its leaders told Endpoints News...
View ArticleClik here to view.
HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants
Takeda spinout HilleVax’s stock $HLVX sunk over 85% on Monday morning after the company announced its norovirus vaccine candidate failed a mid-stage trial in infants. While the vaccine, dubbed HIL-214,...
View ArticleInfections are major cause of non-relapse deaths after CAR-T cell therapy,...
A meta-analysis of CAR-T cell therapy studies found that just over half of cancer patient deaths that are not because of relapse are due to infections. “The main takeaway as clinicians is infections,...
View Article